openPR Logo
Press release

Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR)

08-27-2019 04:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) shares over alleged securities laws violations.

An investor, who purchased shares of Nektar Therapeutics (NASDAQ: NKTR), filed a lawsuit over alleged violations of Federal Securities Laws by Nektar Therapeutics.

Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Francisco, CA based Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. Shares of Nektar Therapeutics (NASDAQ: NKTR) grew from $11.94 per share in early 2017 to as high as $109.32 per share on March 2018.

On August 8, 2019, after-market hours, Nektar Therapeutics announced that a manufacturing issue caused two out of the twenty batches of bempegaldesleukin to differ from the production line. These faulty batches resulted in variable clinical benefit than other batches used in its PIVOT-02 clinical trial.

Shares of Nektar Therapeutics (NASDAQ: NKTR) declined to as low as $17.30 per share on August 14, 2019.

The plaintiff claims that between February 15, 2019 and August 8, 2019, the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) here

News-ID: 1826777 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Nektar

Mead Beverages Market Is Booming So Rapidly | Medovina, Nektar, Kuhnhenn
The "Mead Beverages Market" intelligence report, just published by USD Analytics, covers a micro-level study of important market niches, product offers, and sales channels. To determine market size, potential, growth trends, and competitive environment, the Mead Beverages Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured Redstone
Mead Beverages Market to Eyewitness Massive Growth by 2030 | Redstone, Nektar, M …
Latest Study on Industrial Growth of Global Mead Beverages Market 2022-2028. A detailed study accumulated to offer Latest insights about acute features of the Mead Beverages Market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and
Targeted Therapeutics Market Future Outlook 2022-2028 | Pfizer, Nektar Therapeut …
Targeted therapy is a type of cancer treatment that targets proteins that control the way cancer cells grow, divide, and spread. It is the basis of precision medicine. Rising cancer prevalence and disposable income of people are expected to increase demand for the product. The widespread prevalence of cancer is a major driver for the targeted therapeutics market. Due to the surge in smoking, the number of people affected by it
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics. Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over
Inhalers Market SWOT Analysis | Acorda Therapeutics, Adamis Pharmaceuticals, Ara …
HTF Market Intelligence released a new research report of 357 pages on title 'Inhalers - Medical Devices Pipeline Assessment, 2019' with detailed analysis, forecast and strategies. The study covers key regions and important players such as Acorda Therapeutics Inc, Adamis Pharmaceuticals Corp, Advent Pharmaceuticals Pty Ltd, Aespira Ltd., AKELA Pharma Inc., Alexza Pharmaceuticals Inc, Aradigm Corp, AstraZeneca Plc, Bayer AG, Bellerophon Therapeutics Inc, Bespak Europe Ltd, Boehringer Ingelheim GmbH,
Mead Beverages Global Market 2018: Key Players – Redstone, Brothers Drake, Med …
Mead Beverages Industry Description Wiseguyreports.Com Adds “Mead Beverages -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database The global Mead Beverages market will reach Million USD in 2017 and CAGR xx% 2011-2017. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Mead Beverages by product, region and application, in addition, this report introduces market